/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

MBX BIOSCIENCES INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$33.7 0.0235(2.35%) MBX at 04 Dec 2025 04:38 PM Biotechnology
Lowest Today 33.3
Highest Today 34.45
Today’s Open 33.625
Prev. Close 33.16
52 Week High 34.83
52 Week Low 4.81
Day’s Range: Low 33.3 High 34.45
52-Week Range: Low 4.81 High 34.83
1 day return -
1 Week return -1.82
1 month return +64.22
3 month return +162.02
6 month return +147.84
1 year return +70.25
3 year return -
5 year return -
10 year return -

Institutional Holdings

Market Status

Strong Buy: 3

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 1488.96 M

PB Ratio 3.9962

PE Ratio 4.3009

Enterprise Value 1157.63 M

Total Assets 268.54 M

Volume 840317

Company Financials

Fund house & investment objective

Company Information MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Organisation Biotechnology

Employees 43

Industry Biotechnology

CEO Mr. Peter Kent Hawryluk MBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow